The novel lysophosphatidic acid receptor 1-selective antagonist, ACT-1016-0707, has unique binding properties that translate into effective antifibrotic and anti-inflammatory activity in different models of pulmonary fibrosis.
Birker-Robaczewska M, Boucher M, Ranieri G, Poirey S, Studer R, Freti D, Schnoebelen M, Froidevaux S, Morrison K, Wyss C, Scherer J, Lescop C, Brotschi C, Bolli MH, Kramberg M, Di Stefano S, Rey M, Iglarz M, Delahaye S, Vezzali E, Sieber P, Schäfer A, Caimi SL, Hesse C, Nayler O.
Birker-Robaczewska M, et al. Among authors: iglarz m.
J Pharmacol Exp Ther. 2025 Mar;392(3):103396. doi: 10.1016/j.jpet.2025.103396. Epub 2025 Feb 5.
J Pharmacol Exp Ther. 2025.
PMID: 40073729